Foropafant
Foropafant structure
|
Common Name | Foropafant | ||
|---|---|---|---|---|
| CAS Number | 136468-36-5 | Molecular Weight | 464.70900 | |
| Density | 1.065g/cm3 | Boiling Point | 571.6ºC at 760mmHg | |
| Molecular Formula | C28H40N4S | Melting Point | N/A | |
| MSDS | USA | Flash Point | 299.5ºC | |
|
Platelet-activating factor (PAF) is not an essential component of the cascade leading to smooth muscle cell proliferation following vascular injury.
J. Lipid Mediat. Cell Signal. 12(1) , 49-57, (1995) In order to evaluate the relative importance platelet-activating factor (PAF) in the proliferative process leading to restenosis, the effect of SR 27417, a novel highly potent PAF receptor antagonist, on PAF-induced rabbit aortic smooth muscle cell (SMC) prol... |
|
|
Prevention of platelet-activating factor-induced gastrointestinal lesions in rats by the new specific antagonist N-(2-dimethylaminoethyl)-N-(3-pyridinylmethyl)[4-(2,4,6-triisopropylphe nyl) thiazol-2yl]amine.
Arzneimittelforschung 46(4) , 407-12, (1996) SR 27417 (CAS 136468-36-5, N-(2-dimethylaminoethyl)-N-(3-pyridinylmethyl)[4-(2,4,6-triisop ropylphenyl) thiazol-2-yl]amine), a highly potent platelet-activating factor (PAF) receptor antagonist, was tested for its ability to prevent macroscopic and histologic... |
|
|
Role of platelet activating factor in the intestinal epithelial secretory and Chinese hamster ovary cell cytoskeletal responses to cholera toxin.
Proc. Natl. Acad. Sci. U. S. A. 91(20) , 9655-8, (1994) With the recent heightened concern about cholera around the world come new questions about the mechanism by which cholera toxin causes diarrhea. Peterson and Ochoa have suggested that prostaglandin synthesis is key to both the intestinal epithelial secretory ... |
|
|
Effect of SR 27417, a novel PAF antagonist on antigen-induced hypotension in the rat.
J. Lipid Mediat. Cell Signal. 15(2) , 115-23, (1997) SR 27417, a potent PAF receptor antagonist, inhibited in a dose-dependent manner the hypotensive effect of PAF in rats. It protected rats with an ED50 value of 6 +/- 2 micrograms/kg (n = 6), when given i.v., 1 min before PAF administration. After i.v. adminis... |
|
|
Putative effect of Helicobacter pylori and gastritis on gastric acid secretion in cat.
Am. J. Physiol. Gastrointest. Liver Physiol. 282(4) , G727-34, (2002) Helicobacter pylori may increase or inhibit gastric acid. We studied acid variations and plasma gastrin in cats harboring Helicobacter felis, harboring H. pylori, or free of gastric pathogens with reference to thioperamide (H(3) receptor antagonist) and SR-27... |
|
|
Drug quantitation on a benchtop liquid chromatography-tandem mass spectrometry system.
J. Chromatogr. A. 771(1-2) , 119-25, (1997) The specificity and selectivity of LC-MS-MS is illustrated to explain why LC-MS-MS has become the method of choice for quantitation within the pharmaceutical industry. Two assays are described that demonstrate the facility with which new ion trap technology c... |
|
|
Effect of platelet activating factor antagonists in different models of thrombosis.
Thromb. Res. 76(6) , 503-12, (1994) Effect of three specific PAF antagonists, SR-27417, BN-50739 and ginkgolide derivative BN-52021 have been evaluated in models of thrombosis in the mouse, rat and cat. Thrombosis in the mouse was induced by intravenous infusion of collagen and adrenaline. In r... |
|
|
The role of platelet-activating factor in lipopolysaccharide-induced myocardial depression in guinea pigs.
J. Crit. Care 10(1) , 7-14, (1995) To determine if platelet-activating factor (PAF) is a key mediator of lipopolysaccharide (LPS)-induced myocardial depression in guinea pigs.Hartley guinea pigs of either sex received intraperitoneal (IP) injections of either vehicle (n = 45) or one of three c... |
|
|
Effects of a potent platelet-activating factor antagonist, SR27417A, on allergen-induced asthmatic responses.
Am. J. Respir. Crit. Care Med. 156(1) , 11-6, (1997) Platelet-activating factor (PAF) is a lipid-derived mediator that has been implicated in the pathophysiology of airway inflammation in asthma. Its actions include chemotaxis and activation of inflammatory cells, particularly eosinophils. Inhaled PAF causes br... |
|
|
Effect of a platelet-activating factor (PAF) antagonist, SR 27417A, on PAF-induced gas exchange abnormalities in mild asthma.
Eur. Respir. J. 11(4) , 835-9, (1998) Inhaled platelet-activating factor (PAF), both in normals and in asthmatic patients, provokes transient systemic effects, neutropenia, bronchoconstriction and arterial oxygenation abnormalities similar to those shown in spontaneous exacerbations of asthma. To... |